Cargando…
The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice
Therapeutics that impair the innate immune responses of the liver during the inflammatory cytokine storm like that occurring in COVID-19 are greatly needed. Much interest is currently directed toward Janus kinase (JAK) inhibitors as potential candidates to mitigate this life-threatening complication...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363025/ https://www.ncbi.nlm.nih.gov/pubmed/34952468 http://dx.doi.org/10.1016/j.intimp.2021.108463 |